ReviewCurrent atherosclerosis reports2015
Statin Intolerance: the Clinician's Perspective.
Review in Current atherosclerosis reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.Cardiovascular diabetology · 2025Trial
- Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.Journal of the American College of Cardiology · 2021Trial
- Rational Design and Efficacy Evaluation of a Novel Solid Dispersion-Based Bempedoic Acid-Ezetimibe Fixed-Dose Combination Tablet Versus NexlizetPharmaceutics · 2026Article
- Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.Korean circulation journal · 2026Article
- Gender and region disparities in plasma PCSK9 levels: a systematic review and meta-analysis.BMJ public health · 2026Article
- Breaking down the Dyslipidemia-Stroke Relationship in Southeast Asian American Subgroups: Advancing Toward Cardiovascular Health Equity.Current epidemiology reports · 2025Review
- Decoding the Intricacies of Statin-Associated Muscle Symptoms.Current rheumatology reports · 2024Review
- Delipid extracorporeal lipoprotein filter from plasma system: a new intensive lipid lowering therapy for patients with acute ischemic stroke.Frontiers in neurology · 2024Article
- Bempedoic acid: A nonstatin drug for the management of hypercholesterolemia.Health science reports · 2021Article
- Establishment of an International Collaborative Network for N-of-1 Trials and Single-Case Designs.Contemporary clinical trials communications · 2021Article
- Ascorbic Acid Significantly Decreases Creatine Kinase Plasma Levels in an Animal Model of Statin/Fibrate-Induced Myopathy.Advances in pharmacological and pharmaceutical sciences · 2021Article
- Statin Intolerance in Clinical Practice.Current atherosclerosis reports · 2020Review
- Lysophosphatidic Acid Inhibits Simvastatin-Induced Myocytoxicity by Activating LPA Receptor/PKC Pathway.Molecules (Basel, Switzerland) · 2020Article
- Diagnosis and Management of Statin Intolerance.Journal of atherosclerosis and thrombosis · 2019 · on this mapReview
- Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice.BMC family practice · 2018Article
- Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.Diabetes, obesity & metabolism · 2018Article
- Management of Statin Intolerance in 2018: Still More Questions Than Answers.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2018Review
- Nonadherence to statins: individualized intervention strategies outside the pill box.Vascular health and risk management · 2018Review
- Impact of Gender on Satisfaction and Confidence in Cholesterol Control Among Veterans at Risk for Cardiovascular Disease.Journal of women's health (2002) · 2017Article
- Statins redux: A re-assessment of how statins lower plasma cholesterol.World journal of diabetes · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. However, most patients who experience adverse symptoms during statin use are able to tolerate at least some degree of statin therapy. Given the profound cardiovascular benefits derived from statins, an adequate practical approach to statin intolerance is, therefore, of great clinical importance. Statin intolerance can be defined as the occurrence of myalgia or other adverse symptoms that are attributed to statin therapy and that lead to its discontinuation. In reality, these symptoms are actually unrelated to statin use in many patients, especially in those with atypical presentations following long periods of treatment. Thus, the first step in approaching patients with adverse symptoms during the course of statin therapy is identification of those patients for whom true statin intolerance is unlikely, since most of these patients would probably be capable of tolerating adequate statin therapy. In patients with statin intolerance, an altered dosing regimen of very low doses of statins should be attempted and, if tolerated, should gradually be increased to achieve the highest tolerable doses. In addition, other lipid-lowering drugs may be needed, either in combination with statins, or alone, if statins are not tolerated at all. Stringent control of other risk factors can aid in reducing cardiovascular risk if attaining lipid treatment goals proves difficult.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.